Leukemia & lymphoma

Keyphrases

Publications

volume 65, number 8, 2024

Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)
Yang Liu, Xiaopeng Ma, Xikun Wu, Xinfeng Hou, Wei Jin, Lina Fu, Xiaolei Xun, Yiling Yu, Zhirong Shen
Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B , high TCL1A expression, or over- expressed MYC/BCL-2. Leukemia & lymphoma 65 (8) (2024)
Andrew Ta, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean-Pierre Blaize, Amna Naqvi, Snegha Ananth, Michael Song, Brian Oliver Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia Lee, Gabriel Roman Souza, Esteban Toro Velez, Ian Mines, Zohra Nooruddin
The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA). Leukemia & lymphoma 65 (8) (2024)
Li Lin, Song Xue, Jiaqi Chen, Cuihong Gu, Jingzheng Zhang, Enhong Xing, Wei Wang, Lihong Wang, Zhihua Zhang
Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient. Leukemia & lymphoma 65 (8) (2024)
Jan Philipp Bewersdorf, Kishan K Patel, Rory Michael Shallis, Nikolai A Podoltsev, Tariq Kewan, Jessica Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M Stein, Scott F Huntington, George Goshua, Amer M Zeidan
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)
Giovanni Palladini, Michaela Liedtke, Wagner Zago, Phil Dolan, Gene G Kinney, Morie A Gertz
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis. Leukemia & lymphoma 65 (8) (2024)
Yang Liu, Xiaopeng Ma, Xikun Wu, Xinfeng Hou, Wei Jin, Lina Fu, Xiaolei Xun, Yiling Yu, Zhirong Shen
Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B , high TCL1A expression, or over- expressed MYC/BCL-2. Leukemia & lymphoma 65 (8) (2024)
Christina von Roemeling, Andrés J M Ferreri, Carole Soussain, Han W Tun, Christian Grommes
Targets and treatments in primary CNS lymphoma. Leukemia & lymphoma 65 (8) (2024)
Jingbo Yu, James Nelson, Taylor Marlin, Evan Braunstein, Michelle Jerry
Direct and indirect costs for patients with myeloproliferative neoplasms. Leukemia & lymphoma 65 (8) (2024)
George Nesr, Simone Claudiani, Dragana Milojkovic, Andrew Innes, Fiona Fernando, Irene Caballes, Patience Mungozi, Richard Szydlo, Silvia Lovato, Channa Jayasena, Jane Apperley
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia. Leukemia & lymphoma 65 (8) (2024)

volume 65, number 9, 2024

Luan Phan, Danielle Hammond, Nathaniel R Wilson, Emma M Groarke, Mrinal M Patnaik, Naveen Pemmaraju
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field. Leukemia & lymphoma 65 (9) (2024)
Takashi Nagayama, Shin-Ichiro Fujiwara, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Daisuke Minakata, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation. Leukemia & lymphoma 65 (9) (2024)
Karolina Bełdzińska-Gądek, Ewa Zarzycka, Krzysztof Pastuszak, Katarzyna Borman, Krzysztof Lewandowski, Jan M Zaucha, Witold Prejzner
Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia. Leukemia & lymphoma 65 (9) (2024)
Vikas K Gupta, Abdulraheem Yacoub, Ruben A Mesa, Claire N Harrison, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Hans-Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J Mattison, Carole B Miller, Vinod Parameswaran, Patrick Brown, Christopher Hernandez, Jia Wang, Moshe Talpaz
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial. Leukemia & lymphoma 65 (9) (2024)
Yong Xing, Kaifeng Ye, Chunyuan Li, Jinyao He, Fei Dong, Yun Tian
Risk factors for treatment-related bone loss and osteoporosis in patients with follicular lymphoma. Leukemia & lymphoma 65 (9) (2024)
Takashi Nagayama, Shin-Ichiro Fujiwara, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Takashi Oyama, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Daisuke Minakata, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda
Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation. Leukemia & lymphoma 65 (9) (2024)
Georgina Gener-Ricos, Juan José Rodríguez Sevilla, Samuel Urrutia, Alex Bataller, Alexandre Bazinet, Guillermo Garcia-Manero
Advances in the management of higher-risk myelodysplastic syndromes: future prospects. Leukemia & lymphoma 65 (9) (2024)
Peter A von dem Borne, Berit M Kemps-Mols, Liesbeth C de Wreede, Adriaan A van Beek, Tjeerd J F Snijders, Daniëlle van Lammeren, Janneke Tijmensen, Aniko Sijs-Szabó, Mirjam A Oudshoorn, Constantijn J M Halkes, Peter van Balen, W A Erik Marijt, Jennifer M L Tjon, Joost S P Vermaat, Hendrik Veelken
The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide. Leukemia & lymphoma 65 (9) (2024)
Farhad Ravandi, Marion Subklewe, Roland Bruno Walter, Pankit Vachhani, Gert Ossenkoppele, Veit Buecklein, Hartmut Döhner, Mojca Jongen-Lavrencic, Claudia D Baldus, Lars Fransecky, Timothy S Pardee, Hagop M Kantarjian, Priscilla K Yen, Lata Mukundan, Bharat Panwar, Marc R Yago, Suresh Agarwal, Sophia K Khaldoyanidi, Anthony Stein
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study. Leukemia & lymphoma 65 (9) (2024)
Georgina Gener-Ricos, Juan José Rodríguez Sevilla, Samuel Urrutia, Alex Bataller, Alexandre Bazinet, Guillermo Garcia-Manero
Advances in the management of higher-risk myelodysplastic syndromes: future prospects. Leukemia & lymphoma 65 (9) (2024)
Yongzhi Zheng, Jiazheng Li, Hong Wen, Kaizhi Weng, Shuquan Zhuang, Xingguo Wu, Jian Li, Hao Zheng, Xueling Hua, Zaisheng Chen, Jianda Hu, Shaohua Le
Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020. Leukemia & lymphoma 65 (9) (2024)
Jessica M Stempel, Rory Michael Shallis, Rong Wong, Nikolai A Podoltsev
Challenges in management of older patients with chronic myeloid leukemia. Leukemia & lymphoma 65 (9) (2024)
Alexander Coltoff, Andrew Kuykendall
Emerging drug profile: JAK inhibitors. Leukemia & lymphoma 65 (9) (2024)
Luan Phan, Danielle Hammond, Nathaniel R Wilson, Emma M Groarke, Mrinal M Patnaik, Naveen Pemmaraju
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field. Leukemia & lymphoma 65 (9) (2024)
Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary N Steinbach, Samuel Shewan, Lindsay Maxwell, Meghan Vigil, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Glicelda Galarza Fortuna, Douglas Sborov
Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma 65 (9) (2024)
Alexander Coltoff, Andrew Kuykendall
Emerging drug profile: JAK inhibitors. Leukemia & lymphoma 65 (9) (2024)
Cassandra P Wang, Juanita E Ferreira, Alexander Placek, Paibel Aguayo-Hiraldo, Gordana Raca, Brent L Wood, Karin P Miller, Thomas Coates, David R Freyer, Alexandra Elizabeth Kovach
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome. Leukemia & lymphoma 65 (9) (2024)
Jessica M Stempel, Rory Michael Shallis, Rong Wong, Nikolai A Podoltsev
Challenges in management of older patients with chronic myeloid leukemia. Leukemia & lymphoma 65 (9) (2024)
Farhad Ravandi, Marion Subklewe, Roland Bruno Walter, Pankit Vachhani, Gert Ossenkoppele, Veit Buecklein, Hartmut Döhner, Mojca Jongen-Lavrencic, Claudia D Baldus, Lars Fransecky, Timothy S Pardee, Hagop M Kantarjian, Priscilla K Yen, Lata Mukundan, Bharat Panwar, Marc R Yago, Suresh Agarwal, Sophia K Khaldoyanidi, Anthony Stein
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study. Leukemia & lymphoma 65 (9) (2024)
Cassandra P Wang, Juanita E Ferreira, Alexander Placek, Paibel Aguayo-Hiraldo, Gordana Raca, Brent L Wood, Karin P Miller, Thomas Coates, David R Freyer, Alexandra Elizabeth Kovach
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome. Leukemia & lymphoma 65 (9) (2024)
Fabien Despas, Maria Chaouki, Sandra de Barros, Baptiste Bonneau, Ben Allal, Julie Guillermet-Guibert, Loïc Ysebaert
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure. Leukemia & lymphoma 65 (9) (2024)
Peter A von dem Borne, Berit M Kemps-Mols, Liesbeth C de Wreede, Adriaan A van Beek, Tjeerd J F Snijders, Daniëlle van Lammeren, Janneke Tijmensen, Aniko Sijs-Szabó, Mirjam A Oudshoorn, Constantijn J M Halkes, Peter van Balen, W A Erik Marijt, Jennifer M L Tjon, Joost S P Vermaat, Hendrik Veelken
The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide. Leukemia & lymphoma 65 (9) (2024)
Jennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, David McCue, Fadi G Haddad, William Wierda, Alessandra Ferrajoli, Jan Burger, Tareq Abusab, Jeffrey L Jorgensen, Sa A Wang, Keyur Patel, Sanam Loghavi, Susan O'Brien, Farhad Ravandi
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leukemia & lymphoma 65 (9) (2024)
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Evaluating targeted therapies in older patients with TP53 -mutated AML. Leukemia & lymphoma 65 (9) (2024)
Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary N Steinbach, Samuel Shewan, Lindsay Maxwell, Meghan Vigil, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Glicelda Galarza Fortuna, Douglas Sborov
Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma 65 (9) (2024)
Yongzhi Zheng, Jiazheng Li, Hong Wen, Kaizhi Weng, Shuquan Zhuang, Xingguo Wu, Jian Li, Hao Zheng, Xueling Hua, Zaisheng Chen, Jianda Hu, Shaohua Le
Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020. Leukemia & lymphoma 65 (9) (2024)
Hiroshi Hayashi, Yoshihiko Morikawa, Shogo Akahoshi, Kento Ikegawa, Motohiro Matsui, Atsushi Makimoto, Yuki Yuza
Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study. Leukemia & lymphoma 65 (9) (2024)
Yong Xing, Kaifeng Ye, Chunyuan Li, Jinyao He, Fei Dong, Yun Tian
Risk factors for treatment-related bone loss and osteoporosis in patients with follicular lymphoma. Leukemia & lymphoma 65 (9) (2024)
Paul A Wadsworth, Jingjing Zhang, Timothy Miller, Joshua Menke, Jean Oak, Sebastian Fernandez-Pol
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry. Leukemia & lymphoma 65 (9) (2024)
Tareq Abuasab, Shehab Mohamed, Naveen Pemmaraju, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Farhad Ravandi, Wei Qiao, Guillermo Montalban-Bravo, Gautam Borthakur
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leukemia & lymphoma 65 (9) (2024)
Karolina Bełdzińska-Gądek, Ewa Zarzycka, Krzysztof Pastuszak, Katarzyna Borman, Krzysztof Lewandowski, Jan M Zaucha, Witold Prejzner
Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia. Leukemia & lymphoma 65 (9) (2024)
Netanel A Horowitz, Ali Abed Al Wahad, Noam P Bettman, Shimrit Ringelstein-Harlev, Benjamin Brenner, Tami Katz
Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model. Leukemia & lymphoma 65 (9) (2024)
Hiroshi Hayashi, Yoshihiko Morikawa, Shogo Akahoshi, Kento Ikegawa, Motohiro Matsui, Atsushi Makimoto, Yuki Yuza
Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study. Leukemia & lymphoma 65 (9) (2024)
Jennifer Marvin-Peek, Wei-Ying Jen, Hagop M Kantarjian, David McCue, Fadi G Haddad, William Wierda, Alessandra Ferrajoli, Jan Burger, Tareq Abusab, Jeffrey L Jorgensen, Sa A Wang, Keyur Patel, Sanam Loghavi, Susan O'Brien, Farhad Ravandi
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leukemia & lymphoma 65 (9) (2024)
Fabien Despas, Maria Chaouki, Sandra de Barros, Baptiste Bonneau, Ben Allal, Julie Guillermet-Guibert, Loïc Ysebaert
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure. Leukemia & lymphoma 65 (9) (2024)
Paul A Wadsworth, Jingjing Zhang, Timothy Miller, Joshua Menke, Jean Oak, Sebastian Fernandez-Pol
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry. Leukemia & lymphoma 65 (9) (2024)
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Evaluating targeted therapies in older patients with TP53 -mutated AML. Leukemia & lymphoma 65 (9) (2024)
Vikas K Gupta, Abdulraheem Yacoub, Ruben A Mesa, Claire N Harrison, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Hans-Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J Mattison, Carole B Miller, Vinod Parameswaran, Patrick Brown, Christopher Hernandez, Jia Wang, Moshe Talpaz
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial. Leukemia & lymphoma 65 (9) (2024)
Netanel A Horowitz, Ali Abed Al Wahad, Noam P Bettman, Shimrit Ringelstein-Harlev, Benjamin Brenner, Tami Katz
Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model. Leukemia & lymphoma 65 (9) (2024)
Tareq Abuasab, Shehab Mohamed, Naveen Pemmaraju, Tapan M Kadia, Naval Daver, Courtney D DiNardo, Farhad Ravandi, Wei Qiao, Guillermo Montalban-Bravo, Gautam Borthakur
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leukemia & lymphoma 65 (9) (2024)